Daewoong Pharmaceutical's Fexuprazan takes its first step into Africa entering into a partnership with Cooper PharmaSouth Korea-based Daewoong Pharmaceutical has signed an agreement for license and distribution of potassium-competitive acid blocker (P-CAB) type drug Fexuprazan to Morocco, which is the second largest pharmaceutical market in the North Africa. The partnering company is Cooper Pharma, a leading Moroccan pharmaceutical company with presence in Africa and Middle East. Cooper Pharma, founded in 1933, has rapidly expanded its businesses in the pharmaceutical industry, keeping its number one ranking position in Morocco's PPI market, which was estimated to be around KRW75.5 billion in revenue last year. Daewoong intends to propose a new innovative solution to Gastroesophageal reflux disease (GERD) drugs building on Cooper Pharma's significant market dominance and network. By entering into this agreement, Daewoong Pharmaceutical plans to expand its presence of P-CAB drug Fexuprazan in the African pharmaceutical market for GERD.

Source: The North Africa Journal July 26, 2023 13:00 UTC